Internal Medicine, Hematology & Oncology · Houston, TX
NPI
1114996303
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
2130 W Holcombe Blvd, 10th Floor
Houston, TX, 77030
Phone (713) 600-0900
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.4M
69,849 services
Medicare patients, 2024
193
Average age 75
Drug cost, 2024
$4.4M
1,439 prescriptions
Company payments, 2025
$2,299
From 34 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kevin R Hude was code Q0138 (injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)), 19,890 times for 13 patients. In total Kevin R Hude billed 69,849 services in 121 codes, and Medicare paid $1.4M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-02-15.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 19,890 | 13 | $0.28 | $5,489 |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 3,825 | 24 | $0.10 | $394 |
| 85025 Blood Count | Office | 485 | 139 | $7.58 | $3,677 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 321 | 156 | $12.79 | $4,104 |
| 99214 Office E&M - Established | Office | 229 | 74 | $94.38 | $22K |
| 99213 Office E&M - Established | Office | 221 | 135 | $64.78 | $14K |
| 96413 Chemotherapy Administration | Office | 196 | 18 | $99.97 | $20K |
| 96365 Intravenous Infusion, Hydration | Office | 109 | 25 | $47.12 | $5,136 |
| 80047 Clinical Chemistry | Office | 99 | 36 | $13.46 | $1,333 |
| 96372 Injection Administration | Office | 63 | 14 | $11.02 | $694 |
| 36415 Venipuncture Blood Collection | Office | 50 | 28 | $8.65 | $433 |
| 82565 Clinical Chemistry | Office | 32 | 20 | $5.02 | $161 |
| 71260 CT/CTA - Chest | Office | 30 | 20 | $67.75 | $2,033 |
| A9552 Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 28 | 22 | $104.07 | $2,914 |
| 74177 CT/CTA - Abdomen and Pelvis | Office | 28 | 19 | $215.03 | $6,021 |
By year: 2022 $951K for 76,369 services; 2023 $1.6M for 79,890 services; 2024 $1.4M for 69,849 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 485 | 139 | $7.58 | $3,677 |
| 80047 Clinical Chemistry | 99 | 36 | $13.46 | $1,333 |
| 36415 Venipuncture Blood Collection | 50 | 28 | $8.65 | $433 |
| 82565 Clinical Chemistry | 32 | 20 | $5.02 | $161 |
Medicare prescription drug claims, 2024
In 2024, the drug Kevin R Hude prescribed most often to Medicare patients was Abiraterone Acetate, with 141 prescriptions and refills. In total Kevin R Hude wrote 1,439 Medicare prescriptions that cost $4.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Abiraterone Acetate Generic | 141 | 141 | 23 | $469K |
| Prednisone Generic | 112 | 156 | 35 | $552 |
| Letrozole Generic | 106 | 288 | 33 | $2,189 |
| Dexamethasone Generic | 76 | 87 | 36 | $1,696 |
| Xtandi Enzalutamide | 62 | 62 | Under 11 | $680K |
| Tamoxifen Citrate Generic | 48 | 137 | 17 | $1,815 |
| Eliquis Apixaban | 47 | 51 | Under 11 | $29K |
| Granisetron Hcl Generic | 46 | 47 | 41 | $9,446 |
| Ondansetron Odt Ondansetron | 44 | 44 | 37 | $1,281 |
| Loperamide Loperamide Hcl | 44 | 44 | 20 | $453 |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 40 | 40 | 37 | $406 |
| Verzenio Abemaciclib | 36 | 36 | Under 11 | $535K |
| Aprepitant Generic | 33 | 33 | Under 11 | $11K |
| Hydroxyurea Generic | 32 | 70 | Under 11 | $1,275 |
| Olanzapine Generic | 32 | 32 | 13 | $64.58 |
Brand drugs: 339 claims; generic drugs: 1,100 claims; opioid claims: 16.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kevin R Hude $2,299 ($2,299 in general payments such as food, travel and fees) from 34 companies. The largest payer was Novartis Pharmaceuticals Corporation with $302.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 14 | $302 |
| E.R. Squibb & Sons, L.L.C. BMY | 11 | $241 |
| GlaxoSmithKline, LLC. GSK | 7 | $189 |
| Pfizer Inc. PFE | 8 | $171 |
| Eisai Inc. 4523.T | 4 | $122 |
| Daiichi Sankyo Inc. 4568.T | 5 | $122 |
| Merck Sharp & Dohme LLC MRK | 4 | $114 |
| Janssen Biotech, Inc. JNJ | 4 | $89.27 |
| Abbvie Inc. ABBV | 3 | $72.68 |
| BeOne Medicines USA, Inc. ONC | 3 | $65.7 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.